ATE192040T1 - Wirkstoff gegen arteriosklerose - Google Patents

Wirkstoff gegen arteriosklerose

Info

Publication number
ATE192040T1
ATE192040T1 AT95909975T AT95909975T ATE192040T1 AT E192040 T1 ATE192040 T1 AT E192040T1 AT 95909975 T AT95909975 T AT 95909975T AT 95909975 T AT95909975 T AT 95909975T AT E192040 T1 ATE192040 T1 AT E192040T1
Authority
AT
Austria
Prior art keywords
active ingredients
proliferation
smooth muscle
muscle cells
arteriosclerosis
Prior art date
Application number
AT95909975T
Other languages
English (en)
Inventor
Hisao Tomioka
Hidefumi Ohsawa
Masao Moroi
T Kawashima
Original Assignee
Mitsubishi Tokyo Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tokyo Pharm Inc filed Critical Mitsubishi Tokyo Pharm Inc
Application granted granted Critical
Publication of ATE192040T1 publication Critical patent/ATE192040T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
AT95909975T 1994-05-31 1995-02-24 Wirkstoff gegen arteriosklerose ATE192040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11914694 1994-05-31
PCT/JP1995/000277 WO1995032714A1 (fr) 1994-05-31 1995-02-24 Depresseur de l'arteriosclerose

Publications (1)

Publication Number Publication Date
ATE192040T1 true ATE192040T1 (de) 2000-05-15

Family

ID=14754063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909975T ATE192040T1 (de) 1994-05-31 1995-02-24 Wirkstoff gegen arteriosklerose

Country Status (8)

Country Link
US (1) US5840741A (de)
EP (1) EP0766963B1 (de)
KR (1) KR970703147A (de)
AT (1) ATE192040T1 (de)
AU (1) AU702727B2 (de)
CA (1) CA2190750A1 (de)
DE (1) DE69516519T2 (de)
WO (1) WO1995032714A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4171303B2 (ja) * 2001-02-26 2008-10-22 田辺三菱製薬株式会社 腎疾患・腎不全の予防剤及び/又は治療剤
US20070225301A1 (en) * 2006-02-13 2007-09-27 Astion Inflammation Aps Treatment of acne and other diseases
ES2394984T3 (es) * 2006-12-18 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
ATE543501T1 (de) * 2006-12-20 2012-02-15 Cardoz Ab Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen
EP2175845A2 (de) * 2007-07-11 2010-04-21 Cardoz AB Neue kombination zur verwendung bei der behandlung von entzündlichen erkrankungen
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
WO2009007680A2 (en) 2007-07-11 2009-01-15 Cardoz Ab Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
DE102014222804B4 (de) 2014-11-07 2023-12-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung und Verfahren zum Bestimmen einer Wandschubspannung und System zur Erkennung von Arteriosklerose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH9305A (en) * 1970-05-21 1975-08-18 H Hess Trialkoxy quinazolines
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤

Also Published As

Publication number Publication date
CA2190750A1 (en) 1995-12-07
DE69516519T2 (de) 2000-10-12
AU702727B2 (en) 1999-03-04
AU1823995A (en) 1995-12-21
WO1995032714A1 (fr) 1995-12-07
EP0766963A4 (de) 1997-10-29
DE69516519D1 (de) 2000-05-31
EP0766963A1 (de) 1997-04-09
KR970703147A (ko) 1997-07-03
EP0766963B1 (de) 2000-04-26
US5840741A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
MY107341A (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
DE69410121D1 (en) Dihydro pyrazolopyrrole
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
NZ513096A (en) Compositions for treating inflammatory response
ATE161531T1 (de) Acridine-1,8-dionderivate als therapeutisches mittel
TR199902495T2 (xx) Bile�imler.
ATE192040T1 (de) Wirkstoff gegen arteriosklerose
DE69223736T2 (de) Acridine-1,8-Dionderivate als therapeutisches Mittel
DE69519385D1 (de) Chinazolinon-arzneimittel sowie deren verwendung
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
SE9802650D0 (sv) Compounds
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties